Physician profile
Mitchell H Folbe
NPI 1255321683
$30,013.21
in general payments reported to CMS, 2019-2025
75 companies · $3,600 in 2025
The $3,600 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,331 · 2020: $3,280 · 2021: $5,652 · 2022: $3,688 · 2023: $4,282 · 2024: $3,179 · 2025: $3,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,888.15 |
| Education | $173.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,093.21 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $2,086.15 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $1,875.14 | 2019-2025 | Darzalex, Carvykti, Tecvayli |
| Novartis Pharmaceuticals Corporation | $1,689.83 | 2019-2025 | |
| Genentech USA, INC. | $1,483.69 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Merck Sharp & Dohme LLC | $1,270.87 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $1,233.59 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Secura Bio, INC. | $1,200.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $1,140.79 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Genzyme Corporation | $1,042.33 | 2019-2025 | |
| Incyte Corporation | $952.28 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $793.20 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $775.30 | 2019-2025 | |
| Coherus Oncology, INC. | $763.75 | 2020-2024 | |
| Abbvie INC. | $740.67 | 2019-2025 |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $735.75 | 2019-2025 | Reblozyl, Pomalyst |
| Exelixis INC. | $707.00 | 2019-2025 | Cabometyx |
| Asd Specialty Healthcare, LLC | $592.08 | 2019-2023 | |
| Seagen INC. | $489.64 | 2020-2022 | |
| Daiichi Sankyo INC. | $489.41 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Jazz Pharmaceuticals INC. | $371.10 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $334.91 | 2020-2025 | Xpovio |
| Glaxosmithkline, LLC. | $313.41 | 2019-2025 | Ojjaara, Zejula, Jemperli |
| Kite Pharma, INC. | $307.02 | 2020-2025 | Yescarta |
| Beigene USA, INC. | $287.35 | 2020-2025 | Brukinsa, Tevimbra |
| Dova Pharmaceuticals | $282.98 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.15 | 2019-2023 | Iclusig |
| Sobi, INC | $276.47 | 2022-2025 | |
| Gilead Sciences, INC. | $243.55 | 2019-2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $224.71 | 2020-2025 | Onivyde, Somatuline Depot, Tazverik |
| Taiho Oncology, INC. | $222.92 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $213.07 | 2019-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $174.96 | 2019-2025 | Xtandi, Padcev |
| Stemline Therapeutics INC. | $161.65 | 2022-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $155.98 | 2019-2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $152.19 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $143.20 | 2019-2024 | Libtayo |
| Amag Pharmaceuticals, INC. | $138.48 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $136.18 | 2023-2024 | Myrisk, Precisetumor |
| Foundation Medicine, INC. | $131.99 | 2019 | |
| Verastem, INC. | $129.21 | 2019 | |
| Puma Biotechnology, INC. | $126.30 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $119.86 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $119.61 | 2020-2023 | Qinlock |
| Genmab U.S., INC. | $118.44 | 2024-2025 | Epkinly |
| Mirati Therapeutics, INC. | $117.38 | 2023 | Krazati |
| Array Biopharma INC | $113.37 | 2020-2024 | Mektovi, Braftovi, Lorbrena |
| Legend Biotech USA INC. | $102.47 | 2024-2025 | Carvykti |
| Beone Medicines USA, INC. | $96.66 | 2025 | Brukinsa, Tevimbra |
| Spectrum Pharmaceuticals INC. | $86.15 | 2023 | Rolvedon |
| Pharmacosmos Therapeutics INC. | $80.44 | 2023-2024 | Monoferric |
| Adc Therapeutics America, INC. | $78.73 | 2021-2022 | |
| Geron Corporation | $76.29 | 2025 | Rytelo |
| Tersera Therapeutics LLC | $73.82 | 2024 | Zoladex |
| Mylan Institutional INC. | $67.31 | 2019 | |
| Epizyme, INC. | $64.42 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $63.62 | 2025 | Pyrukynd |
| Emd Serono, INC. | $62.75 | 2019-2022 | |
| Morphosys, US INC. | $61.94 | 2021-2023 | Monjuvi |
| Pharmaessentia USA Corporation | $53.76 | 2024 | Besremi |
| Cardinal Health 108 LLC | $53.52 | 2019 | |
| Genentech, INC. | $53.45 | 2025 | Venclexta |
| Aveo Pharmaceuticals, INC. | $45.94 | 2021-2024 | |
| Rigel Pharmaceuticals, INC. | $43.53 | 2023 | Tavalisse, Rezlidhia |
| Acrotech Biopharma INC. | $42.41 | 2021-2024 | Beleodaq |
| Janssen Pharmaceuticals, INC | $42.06 | 2021-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $40.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.51 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $28.09 | 2023 | Sylvant |
| Shield Therapeutics INC | $23.56 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.50 | 2025 | Danziten |
| Caris Mpi, INC. | $17.86 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $17.07 | 2023 | Orgovyx |
| Innate Pharma, INC | $12.95 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
Keytruda $628Venclexta $530Udenyca $518Kisqali $474Lenvima $442Enhertu $406Opdivo $324Carvykti $318Darzalex $287Verzenio $284Tagrisso $267Imbruvica $257Tecvayli $236Imfinzi $220Doptelet $215Brukinsa $209Rybrevant $207Ibrance $196Jakafi $196Reblozyl $195Xpovio $187Injectafer $186Jaypirca $182Onivyde $179Polivy $169Zepzelca $164Tecentriq $163Talvey $155Epkinly $153Sarclisa $151Calquence $150Orserdu $147Lynparza $131Somatuline Depot $128Cabometyx $127Tukysa $122Trodelvy $121Piqray $119Krazati $117Myrisk $117Phesgo $112Lunsumio $104Ojjaara $103Alecensa $93.70Rolvedon $86.15Tibsovo $85.80Welireg $83.12Monoferric $80.44Yescarta $79.86Inqovi $77.90Lonsurf $77.90Rytelo $76.29Zoladex $73.82Monjuvi $71.56Columvi $70.65Xtandi $70.08Zejula $69.98Jemperli $69.98Erleada $66.50Itovebi $65.76Libtayo $63.87Pyrukynd $63.62Retevmo $62.65Perjeta $61.78Kadcyla $61.78Tevimbra $60.02Keytruda Qlex $57.04Ultomiris $56.79Fabhalta $53.98Opdualag $53.81Besremi $53.76Lupron Depot $53.61Kyprolis $51.27Pomalyst $51.08Scemblix $48.80Ayvakit $48.31Mektovi $47.43Braftovi $47.43Idhifa $46.92Vectibix $44.50Nplate $44.50Rezlidhia $43.53Tavalisse $43.53Xgeva $41.47Blincyto $37.93Rozlytrek $35.37Lumakras $32.16Promacta $29.61Sylvant $28.09Lorbrena $27.86Akeega $27.26Balversa $27.26Datroway $27.23Qinlock $25.93Lucentis $25.91Padcev $25.43Accrufer $23.56Zynyz $21.94Danziten $21.50Augtyro $20.40
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Folbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.